The patients with the BIM gene no polymorphism have longer the median progression-free time than the polymorphism types in retreatment advanced non-small cell lung cancer patients with tyrosine kinase inhibitor. The gene discussed is BCL2L11; the disease is non-small cell lung carcinoma.